Understanding the mechanisms of rare neuromuscular and neurodegenerative diseases to develop new therapies.
Click here to access our DM2 atlas appOur lab studies the molecular basis of genetic neuromuscular diseases and builds preclinical models and oligonucleotide-based therapies to bring new treatments to patients.
Myotonic dystrophy (DM1 and DM2) is caused by CTG and CCTG repeat expansions in the DMPK and CNBP genes. We investigate muscle atrophy and gastrointestinal symptoms, develop new preclinical models and oligonucleotide therapeutics, and lead the first Spanish registry of DM1 patients (the DM1-Hub project), using whole-genome sequencing to identify genetic modifiers.
Limb-girdle muscular dystrophy D2 is caused by a pathogenic 15-amino-acid tail in transportin-3 (TNPO3), which disrupts its nuclear import function. We developed the first Drosophila, cell and mouse models of the disease and now study subcellular proteomics and structure, drug repurposing, and oligonucleotides that modulate TNPO3 expression.
We address cancer-associated cachexia, the progressive loss of skeletal muscle mass in cancer patients, using advanced preclinical models to understand how tumor-derived factors drive muscle catabolism. In parallel, we develop precision approaches against aggressive CNS tumors such as glioblastoma, targeting key molecular drivers with selective inhibitors.
Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome is a rare neurodegenerative disorder linked to an expanded AAGGG repeat in the RFC1 gene. We are building the first Drosophila model expressing this repeat to study its toxic effects and enable drug screening.
We have long worked on oligonucleotide strategies such as antimiRs and gapmers that improved disease phenotypes in myotonic dystrophy models. We now focus on better delivery to skeletal muscle, including bichromatic reporters to track intracellular activity, plus proteomic and structural studies.
Drosophila offers fast development, genetic simplicity and conserved pathways. We have used it to model myotonic dystrophy, SMA and LGMDD2 and to identify drug candidates, and we are now generating precise transgenic models for high-throughput drug screening.
We proudly support International Myotonic Dystrophy Awareness Day, observed every year on September 15th, to raise awareness and promote understanding of this condition.
Support our research DM Awareness Day